

Mitogen 및 *Mycoplasma* 항원 자극시 사람 비강 섬유아세포에서 Nitric Oxide와 Interleukin-1의 생성에 미치는 효과

이한국¹ · 김광혁² · 유태현¹ · 이강대¹ · 이봉희¹ · 이윤우¹ · 장명웅²

Effects of Nitric Oxide and Interleukin-1 Produced by Human Nasal Fibroblast Stimulated by Mitogens and *Mycoplasma* Antigens

Han Kook Lee, MD¹, Kwang Hyuk Kim, PhD², Tai Hyun Yu, MD¹,
Kang Dae Lee, MD¹, Bong Hee Lee, MD¹,
Woon-Woo Lee, MD¹ and Myung Woong Chang, PhD²

¹Department of Otolaryngology-Head and Neck Surgery, ²Microbiology, College of Medicine,
Kosin University, Pusan, Korea

— ABSTRACT —

Background and Objectives : Excessive cytokine expression and nitric oxide (NO) induced by stimuli such as microbial products may be one aspect of the inflammatory response associated with bacteremia. We evaluated effects of mitogens and *Mycoplasma* antigens on the biological activity of human nasal fibroblast. **Materials and Methods** : We have undertaken a study of the kinetics of NO and interleukin-1 (IL-1) production in human nasal fibroblast culture exposed with lipopolysaccharide (LPS) of gram negative bacteria, *Staphylococcus enterotoxin B* (SEB), or *Mycoplasma* lysates. This study was designed to evaluate NO and IL-1 in the fibroblast culture supernatant by assays of nitrite ion concentration and mouse thymocyte cultivation. **Results** : 1) The NO production was increased by 0.01 µg/ml of LPS, all doses of SEB (0.001 -1.0 µg/ml), or all kinds of *Mycoplasma* lysates (*M. pneumoniae*, *M. fermentans*, *M. hominis*), but decreased by 0.001, 0.1, and 1.0 µg/ml of LPS. 2) The IL-1 production was significantly increased by all doses of LPS (0.001 -1.0 µg/ml), SEB (0.001 -1.0 µg/ml), or *Mycoplasma* lysates. 3) In the culture supernatants of the fibroblast exposed to double stimuli, LPS plus SEB, LPS plus *Mycoplasma* lysates, the NO concentrations were higher than in those exposed to LPS alone. 4) The fibroblast responded differently to double exposure with stimuli in the production of IL-1. The IL-1 concentration increased or decreased according to doses and kinds of stimuli as compared with those exposed to LPS alone. Especially, the group exposed with LPS (0.01 µg/ml) plus *Mycoplasma* lysates showed highly significant increase of IL-1 as compared with the group exposed to LPS (0.01 µg/ml) alone. **Conclusion** : It is therefore believed that NO and IL-1 production in human nasal fibroblast increased mostly by not only LPS, but also SEB. Moreover, its increase by *Mycoplasma* lysates was remarkable. Excessive NO and IL-1 production elicited by double exposure with stimuli *in vivo* may effect on the inflammatory reactions and cytokines production. (**J Clinical Otolaryngol 1999;10:202-210**)

KEY WORDS : Human fibroblast culture · Lipopolysaccharide · *Staphylococcus enterotoxin B* · *Mycoplasma* lysates · Nitric oxide · Interleukin-1.

: 1999 3 10

: 1999 4 30

: , 602 - 702

34

: (051) 240 - 6277 · : (051) 245 - 8539

E - mail : hkleee@ns.kosinmed.or.kr

: Mitogen *Mycoplasma*

Nitric Oxide Interleukin - 1

서 론

NO IL - 1

가

Nitric oxide(NO)

재료 및 방법

NO

섬유아세포의 배양

2 5 mm³

1 mm³

¹⁾²⁾

, FeS

(fetal calf serum, FCS, Boeh -
ringer Mannheim, Mannheim, Germany) 10%

, DNA

Eagle's minimum essential medium(EM - EM,
Gibco, Grand Island, USA) 2 ml 60 mm

NO

(Costar, Cambridge, USA)

³⁾

Interleukin - 1(IL - 1) (lipopolysac -
caride, LPS), muramylpeptide, phobolester,

cover slip

37 , 5% CO₂

(C3a,C5a), IFN, TNF, colony

. 3 4

stimulating factor(CSF), transforming growth

. 3

factor - (TGF -),

phosphate bu -

가

ffered saline(PBS) 1

0.25% trypsin

ngerhans' cell, microglial cell)

. IL -

5

1 T

TCR

10% FCS EMEM

NO

IL - 1R

T

IL - 1

IL - 2, IL - 3

. B

B

Mycoplasma 항원, LPS 및 SEB 의 준비

T NK

Deep freezer

Mycoplasma

meostasis

M. pneumoniae(Mp), *M. fermentans*(Mf), *M. hom -*
inis(Mh) Chanock 5 ml

IL - 1

5 7

100

modynamic shock),

(he -

g 1

PBS 3

20 ml PBS

,

⁴⁻⁶⁾

.

100 watt

10

sonication

(primary culture)

(Sigma, St. Louis, USA)

LPS,

Staphylococcus ent -

섬유아세포 배양상층액의 준비

erotoxin B(SEB),

Mycoplasma

(2.5 × 10⁵/ml) 1 ml

24 we -

lls

plate(Corning, NY, USA)

ml LPS 0.001, 0.01, 0.1, 1.0 μ g, SEB 0.001, 0.01, 0.1, 1.0 μ g, *Mycoplasma* (Mp, Mf, Mh) 1 μ g .
 LPS 0.001, 0.01, 0.1, 1.0 μ g
 SEB 0.001, 0.01, 0.1, 1.0 μ g 가
 LPS 0.001, 0.01, 0.1, 1.0 μ g
Mycoplasma (Mp, Mf, Mh) 1 μ g
 가 . 37 , 5% CO₂
 24 .
 well triplicate .
 300 g 30
 - 70 NO IL - 1

NO 정량분석

NO nitrite Nitrite
 nitrite .
 Ding ⁷⁾ microplate
 .
 0.1 ml 96 wells microplate(Corning, NY, U.S.A.)
 Griess [1% sulfanilamide(Sigma, St. Louis, USA)/0.1% naphthylethylene diamine dihydrochloride(Sigma, St. Louis, USA)/2.5% phosphoric acid(Junsei, Osaka, Japan)] 0.1 ml
 10 . Optical density microplate reader (Model 550 microplate reader, Bio - Rad, Richmond, U.S.A.) 540 nm sodium nitrite(Hayashi, Tokyo, Japan)

IL-1의 측정

IL - 1 (8-11)
 가 가 (1
 $\times 10^7$ cells/ml) 0.1 ml 96 wells microplate
 concanavalin A (4 μ g/ml) 50 μ l
 50 μ l . plate 37 , 5%
 CO₂ 48 .
 well tetrazolium salt MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium br-

omide, 5 mg/ml in PBS] 10 μ l 가 4
 30 가 well sodium
 dodecyl sulfate(10% w/v SDS in 0.02M HCl) 25
 μ l
 . Optical density microplate reader(Model 550 microplate reader, Bio - Rad, Richmond, U.S.A.)
 540nm . stand -
 ard interleukin - 1 (Boehringer Mannheim, Mannheim, Germany)

통계학적 분석

\pm
 Student's t - test
 p 0.05

결 과

LPS, SEB, *Mycoplasma*
 , LPS
 SEB *Mycoplasma*
 NO IL - 1
 LPS, SEB, *Mycoplasma* 항원에 단독노출시 NO 생성능
 LPS
 NO Table 1 . LPS 0.
 001 1.0 μ g/ml
 . SEB 0.001 1.0 μ g/ml

Table 1. NO release in cultures of human nasal fibroblast with LPS

Nitrite conc. (μ M/L)	
LPS(g/ml)	
0.001	6.87 \pm 0.20
0.01	7.15 \pm 0.19
0.1	6.64 \pm 0.26
1.0	6.01 \pm 0.39
Control	7.06 \pm 0.19

Human nasal fibroblasts were cultivated with LPS for 24 hrs. Nitrite was measured in the culture supernatant. Data are mean \pm SDM

: Mitogen *Mycoplasma*

Nitric Oxide Interleukin - 1

LPS
가 1.0 µg/ml 가
(p<0.05, Table 2). *Mycoplasma*
LPS SEB 가 .
Mp Mh 가 (p<0.05, Table 3).
LPS, SEB, *Mycoplasma* 항원에 단독노출시 IL-1 생성능
LPS 0.001 1.0 µg/ml
IL - 1 Table 4
. NO
LPS
1.0 µg/ml 4 (p<0.01). SEB
(p<0.01, Table 5). *Myco* -
plasma 1 µg/ml IL - 1
가 (p<0.01). Mf(
7), Mh(3), Mp(1.7)
(Table 6).

LPS, SEB, *Mycoplasma* 항원에 중복노출시 NO 생성능
0.001 µg/ml LPS SEB 0.001
1.0 µg/ml 가 , LPS
SEB 0.01 µg/ml 0.1 µg/
ml NO 가 (p<0.05). 0.01
µg/ml LPS SEB 0.001 1.0 µg/
ml , LPS 0.01 µg/ml
SEB
가 SEB 0.01 µg/ml 가

Table 2. NO release in cultures of human nasal fibroblast with SEB

	Nitrite conc. (M/L)
SEB (µ g/ml)	
0.001	7.42 ± 0.19
0.01	7.10 ± 0.52
0.1	7.24 ± 0.32
1.0	7.87 ± 0.20*
Control	7.06 ± 0.19

Human nasal fibroblasts were cultivated with SEB for 24 hrs. Nitrite was measured in the culture supernatant. Datas are mean ± SDM, *p<0.05 versus the control

Table 3. NO release in cultures of human nasal fibroblast with *Mycoplasma* lysates

	Nitrite conc.(M/L)
Lysates (1 µ g/ml)	
<i>M. pneumoniae</i>	8.86 ± 0.43*
<i>M. fermentans</i>	7.55 ± 0.13
<i>M. hominis</i>	8.69 ± 0.33*
Control	7.06 ± 0.19

Human nasal fibroblasts were cultivated with *Mycoplasma* lysates for 24 hrs. Nitrite was measured in the culture supernatant. Datas are mean ± SDM. *p<0.05 versus the control

Table 4. IL-1 levels in cultures of human nasal fibroblast with LPS

	IL-1 conc.(units/ml)
LPS (µ g/ml)	
0.001	65.81 ± 2.38*
0.01	71.81 ± 1.55*
0.1	84.55 ± 1.18*
1.0	128.40 ± 5.61*
Control	33.71 ± 1.91

Human nasal fibroblasts were cultivated with LPS for 24 hrs. IL-1 was measured in the culture supernatant. Datas are mean ± SDM. *p<0.01 versus the control

Table 5. IL-1 levels in cultures of human nasal fibroblast with SEB

	IL-1 conc.(units/ml)
SEB (µ g/ml)	
0.001	52.16 ± 2.67*
0.01	58.04 ± 1.92**
0.1	69.35 ± 2.62**
1.0	86.42 ± 7.64**
Control	33.71 ± 1.91

Human nasal fibroblasts were cultivated with SEB for 24 hrs. IL-1 was measured in the culture supernatant. Datas are mean ± SDM. *p<0.05 versus the control, **p<0.01 versus the control

Table 6. IL-1 levels in cultures of human nasal fibroblast with *Mycoplasma* lysates

	IL-1 conc.(units/ml)
Lysates(1 µ g/ml)	
<i>M. pneumoniae</i>	55.83 ± 1.20*
<i>M. fermentans</i>	222.43 ± 6.42*
<i>M. hominis</i>	102.20 ± 4.02*
Control	33.71 ± 1.91

Human nasal fibroblasts were cultivated with *Mycoplasma* lysates for 24 hrs. IL-1 was measured in the culture supernatant. Datas are mean ± SDM. *p<0.01 versus the control

(p<0.05). LPS 0.1 µg/ml , sma 가 , LPS 0.001 µg/ml , NO Mf Mh

SEB 0.001 1.0 µg/ml , LPS 0.001 µg/ml NO

(p<0.05). LPS 1.0 µg/ml (p<0.05). LPS 0.1 µg/ml My -

SEB 0.001 1.0 µg/ml , coplasma , LPS

SEB 0.01 µg/ml 0.1 µg/ml 가 가 (p<0.05). LPS 1.0 µg/ml

(p<0.05, Fig.1). Mycoplasma LPS Mp, Mf, Mh

0.001 µg/ml LPS Mycoplasma 1 µg/ml 가 NO (p<0.05, Fig.2).

, Mp, Mf, Mh 1 µg/ml 가 LPS, SEB, Mycoplasma 항원에 중복노출시 IL-1 생성능

, LPS 0.001 µg/ml 가 IL - 1 LPS 0.001 µg/ml

Mp 가 LPS, SEB, Mycoplasma 항원에 중복노출시 IL-1 생성능

Mf Mh 가 (p< 0.05). IL - 1 LPS 0.001 µg/ml

0.05). 0.01 µg/ml LPS Mycopla - SEB 0.001 1.0 µg/ml , LPS




Fig. 1. NO release in the cultures of human nasal fibroblast exposed to LPS and SEB. Supernatants were collected after 24 hrs. Cultures were exposed to LPS (0.001, 0.01, 0.1, 1.0 g/ml) plus SEB (0.001, 0.01, 0.1, 1.0 g/ml) during the entire culture period. Datas are mean ± SDM. *Significantly different from the corresponding control value (SEB-free group, p<0.05). †Significantly different from the LPS-free group at the same SEB concentration (p<0.05).




Fig. 2. NO release in the cultures of human nasal fibroblast exposed to LPS and Mycoplasma lysates. Supernatants were collected after 24hrs. Cultures were exposed to LPS (0.001, 0.01, 0.1, 1.0 g/ml) plus Mycoplasma lysates (*M. pneumoniae* (Mp), *M. fermentans* (Mf), *M. hominis* (Mh), 1.0 g/ml each) during the entire culture period. Datas are mean ± SDM. *Significantly different from the corresponding control value (Mycoplasma-free group, p<0.05). †Significantly different from the LPS-free group at the same Mycoplasma (p<0.05).

: Mitogen *Mycoplasma*

Nitric Oxide Interleukin - 1

0.001 $\mu\text{g/ml}$ SEB 0.001 1.0 $\mu\text{g/ml}$ 가 ($p < 0.01$, Fig.3).
 $\mu\text{g/ml}$ ($p < 0.05$). SEB 0.01 $\mu\text{g/ml}$ 가 LPS 0.001 $\mu\text{g/ml}$ *Mycoplasma*
 05) SEB 0.01, 0.1, 1.0, 1.0 $\mu\text{g/ml}$, IL - 1
 가 (LPS 0.01 $\mu\text{g/ml}$ SEB 가 LPS Mp, Mh, Mf ($p < 0.01$). LPS 0.01
 . LPS 0.01 $\mu\text{g/ml}$ SEB $\mu\text{g/ml}$ *Mycoplasma*
 IL - 1 SEB 가 , *Mycoplasma*
 LPS 0.01 $\mu\text{g/ml}$ 가 LPS LPS IL - 1
 ($p < 0.01$). LPS 0.1 $\mu\text{g/ml}$ 가 ($p < 0.01$). LPS 0.1 $\mu\text{g/ml}$
 SEB SEB 가 LPS LPS IL - 1
 LPS SEB *Mycoplasma* , Mf Mh
 1.0 $\mu\text{g/ml}$ 가 ($p < 0.01$). LPS 1.0 $\mu\text{g/ml}$ 가 LPS 가 Mp
 SEB , . LPS 1.0 $\mu\text{g/ml}$
 SEB LPS *Mycoplasma* , My -




Fig. 3. IL-1 production in the cultures of human nasal fibroblast exposed to LPS and SEB. Supernatants were collected after 24hrs. Cultures were exposed to LPS (0.001, 0.01, 0.1, 1.0 g/ml) plus SEB (0.001, 0.01, 0.1, 1.0 g/ml) during the entire culture period. Datas are mean \pm SDM. *Significantly different from the corresponding control value (SEB-free group, $p < 0.05$). †Significantly different from the LPS-free group at the same SEB concentration ($p < 0.05$).




Fig. 4. IL-1 production in the cultures of human nasal fibroblast exposed to LPS and *Mycoplasma* lysates. Supernatants were collected after 24hrs. Cultures were exposed to LPS (0.001, 0.01, 0.1, 1.0 g/ml) plus *Mycoplasma* lysates (*M. pneumoniae* (Mp), *M. fermentans* (Mf), *M. hominis* (Mh), 1.0 g/ml each) during the entire culture period. Datas are mean \pm SDM. *Significantly different from the corresponding control value (*Mycoplasma*-free group, $p < 0.05$). †Significantly different from the LPS-free group at the same *Mycoplasma* ($p < 0.05$).

Mycoplasma 가 SEB 0.001
Mf Mh LPS IL - 1 1.0 µg/ml
가 Mp (Fig. 4).
고 찰 . *Mycoplasma* 1.0 µg/ml
NO NO IL - 1 LPS, SEB, *Mycoplasma*
가 NO 가 NO
nitric oxide sy IL - 1 가
ynthase(NOS) NO LPS 0.
NO 001 µg/ml SEB 가 LPS
³⁾ 가 NO SEB 0.01, 0.1 µg/ml
가 NO 가 *Mycoplasma* 가
가 NO 가 LPS Mf, Mh 가 LPS 0.01 µg/
NO TNF - ml SEB 가 LPS
¹²⁾ Staphyloco SEB 0.01 µg/ml 가
ccal exotoxins toxic shock syndrome toxin 1(TS - *Mycoplasma* 가 Mf
ST - 1) SEB Mh . LPS 0.1 µg/ml
NO SEB 가 LPS
¹³⁻¹⁵⁾ NO 가 *Mycoplasma*
가 . LPS 1.0 µg/
IL - 1 T , B , ml SEB 가 LPS
가 SEB LPS 0.001 µg/ml
LPS . *Mycoplasma*
¹⁶⁾ LPS 0.1 µg/ml 가
IL - 1 (me -
mbrane - associated cytokine) . TSST -
1, SEB, *Mycoplasma* IL - 1
¹⁷⁻²⁰⁾ NO 가
IL - 1 (septic shock), IL - 1 LPS
, , 0.001 µg/ml SEB 가 LPS
IL - 1
. SEB 0.001 µg/ml
0.01, 0.1, 1.0 µg/ml
sma LPS SEB *Mycopla* - 가 . SEB 0.001 µg/
asma NO ml 가 . *Mycoplasma*
IL - 1 가 가
NO LPS 0. 가 . LPS 0.01 µg/ml SEB 가
001 1.0 µg/ml 0.01 µg/ml LPS SEB

: Mitogen *Mycoplasma* Nitric Oxide Interleukin - 1

Mycoplasma SEB *Mycoplasma*
NO IL - 1

가 . LPS 0.1 $\mu\text{g/ml}$ SEB 가 가
LPS 0.01 $\mu\text{g/ml}$

SEB 1.0 $\mu\text{g/ml}$. My - NO IL - 1
coplasma 가 LPS 0.01 $\mu\text{g/}$ LPS SEB
ml . , Mp . My -
가 Mf Mh 가 *coplasma* .

. LPS 1.0 $\mu\text{g/ml}$ SEB 가 가

IL - 1 중심 단어 : . Interleukin - 1.

Mycoplasma
Mp, Mf, Mh LPS
(0.001, 0.01 $\mu\text{g/ml}$) IL - 1
Mycoplasma
, LPS IL -

1

결 론

LPS, SEB *Mycoplasma*
NO IL - 1

LPS NO
(0.01 $\mu\text{g/ml}$) , IL -

1 (0.001 1.0 $\mu\text{g/ml}$)
. SEB NO IL -

1 . *Mycoplasma*
NO , IL - 1

Mycoplasma
. Mf 6
Mp 1.5
LPS

REFERENCES

- 1) Lowenstein CJ, Snyder SH. Nitric oxide, a novel biologic messenger. *Cell* 1992;70:705-7.
- 2) Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or-independent mechanisms. *Cancer Res* 1994;54:2462-7.
- 3) Maeda H, Akaike T, Yoshida M, Suga M. Multiple functions of nitric oxide in pathophysiology and microbiology: analysis by a new nitric oxide scavenger. *J Leukoc Biol* 1994;56:588-92.
- 4) Ogle CK, Wu JZ, Mao X, Szczur K, Alexander JW, Ogle JD. Heterogeneity of Kupffer cells and splenic, alveolar, and peritoneal macrophages for the production of TNF, IL-1, and IL-6. *Inflammation* 1994;18:511-23.
- 5) Natanson C, Danner RL, Elin RJ, Hosseini JM, Peart KW, Banks SM, et al. Role of endotoxemia in cardiovascular dysfunction and mortality: *Escherichia coli* and *Staphylococcus aureus* challenges in a canine model of human septic shock. *J Clin Invest* 1989;83:243-51.
- 6) Dinarello CA. Interleukin-1 and interleukin-1 antagonism. *Blood* 1991;77:1627-52.
- 7) Ding AH, Nathan CF, Stuehr J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. *J Immunol* 1988;141:2407-12.
- 8) Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. *J Exp Med* 1972;136:128-42.
- 9) Gilis S, Mizel SB. T cell lymphoma model for the analysis of interleukin-1-mediated T-cell activation. *Proc Natl Aca Sci USA* 1981;78:1133-7.
- 10) Gearing AJ, Bird CR, Bristow A, Poole S, Thorpe R. A

- simple sensitive bioassay for interleukin-1 which is unresponsive to 103 units of interleukin-2. J Immunol Methods* 1987;99:7-11.
- 11) Mosmann T. *Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods* 1983;65:55-63.
 - 12) Lee HJ, Kim NY, Jang MK, Son HJ, Kim KM, Sohn DH, et al. *A sesquiterpene, dehydrocostus lactone, inhibits the expression of inducible nitric oxide synthase and TNF-alpha in LPS-activated macrophages. Planta Med* 1999; 65:104-8.
 - 13) Fast DJ, Shannon BJ, Herriott MJ, Kennedy MJ, Rummage JA, Leu RW. *Staphylococcal exotoxins stimulate nitric oxide-dependent murine macrophage tumoricidal activity. Infect Immun* 1991;59:2987-93.
 - 14) Cunha FQ, Moss DW, Leal LM, Moncada S, Liew FY. *Induction of macrophage parasitocidal activity by Staphylococcus aureus and exotoxins through the nitric oxide synthesis pathway. Immunol* 1993;78:563-7.
 - 15) Zembowicz A, Vane JR. *Induction of nitric oxide synthase activity by toxic shock syndrome toxin I in a macrophage-monocyte cell line. Proc Natl Acad Sci USA* 1992;89: 2051-5.
 - 16) Kozak W, Kluger MJ, Soszynski D, Conn CA, Rudolph K, Leon LR, et al. *IL-6 and IL-1 beta in fever. Studies using cytokine-deficient (knockout) mice. Ann N Y Acad Sci* 1998;856:33-47.
 - 17) Parsonnet J, Hickman RK, Eardley DD, Pier GB. *Induction of human interleukin-1 by toxic-shock-syndrome toxin-1. J Infect Dis* 1985;151:514-22.
 - 18) Muhlradt P, Schade U. *MDHM, a macrophage-stimulatory product of Mycoplasma fermentans, leads to in vitro IL-1, IL-6, tumor necrosis factor, and prostaglandin production and is pyrogenic in rabbits. Infect Immun* 1991;59:3969-74.
 - 19) Litton MJ, Sander B, Murphy E, O'Garra A, Abrams JS. *Early expression of cytokines in lymph nodes after treatment in vivo with Staphylococcus enterotoxin B. J Immunol Methods* 1994;175:47-58.
 - 20) Ruetten H, Thiemermann C. *Combination immunotherapy which neutralises the effects of TNF alpha and IL-1 beta attenuates the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. J Physiol Pharmacol* 1997;48:605-21.